These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 19427302

  • 1. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
    La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D, Petronini PG.
    Biochem Pharmacol; 2009 Sep 01; 78(5):460-8. PubMed ID: 19427302
    [Abstract] [Full Text] [Related]

  • 2. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov 01; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 3. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y, Chen Y, Mei Q, Chen Y, Yu S, Xia S.
    Oncol Rep; 2013 Jun 01; 29(6):2486-92. PubMed ID: 23525575
    [Abstract] [Full Text] [Related]

  • 4. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.
    Mol Cancer Res; 2010 Aug 01; 8(8):1142-51. PubMed ID: 20647329
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 6. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F.
    Clin Cancer Res; 2013 Jul 01; 19(13):3508-19. PubMed ID: 23695170
    [Abstract] [Full Text] [Related]

  • 7. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY.
    Clin Cancer Res; 2007 May 01; 13(9):2795-803. PubMed ID: 17473213
    [Abstract] [Full Text] [Related]

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 9. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY, Zhao MB, Zhuang GB, Li PP.
    Lung Cancer; 2012 Jan 01; 75(1):30-7. PubMed ID: 21757251
    [Abstract] [Full Text] [Related]

  • 10. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K.
    Neuroendocrinology; 2012 Jan 01; 96(3):228-37. PubMed ID: 22378048
    [Abstract] [Full Text] [Related]

  • 11. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.
    Cancer Chemother Pharmacol; 2010 Jul 01; 66(2):381-8. PubMed ID: 19921194
    [Abstract] [Full Text] [Related]

  • 12. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
    Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G.
    Int J Cancer; 2006 Jan 01; 118(1):209-14. PubMed ID: 16003751
    [Abstract] [Full Text] [Related]

  • 13. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
    Yasugi M, Takigawa N, Ochi N, Ohashi K, Harada D, Ninomiya T, Murakami T, Honda Y, Ichihara E, Tanimoto M, Kiura K.
    Exp Cell Res; 2014 Aug 15; 326(2):201-9. PubMed ID: 24768699
    [Abstract] [Full Text] [Related]

  • 14. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.
    Int J Mol Med; 2007 Jul 15; 20(1):3-10. PubMed ID: 17549382
    [Abstract] [Full Text] [Related]

  • 15. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA.
    Cancer Res; 2004 Oct 15; 64(20):7241-4. PubMed ID: 15492241
    [Abstract] [Full Text] [Related]

  • 16. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):577-84. PubMed ID: 16532343
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
    Ando K, Ohmori T, Inoue F, Kadofuku T, Hosaka T, Ishida H, Shirai T, Okuda K, Hirose T, Horichi N, Nishio K, Saijo N, Adachi M, Kuroki T.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8872-9. PubMed ID: 16361577
    [Abstract] [Full Text] [Related]

  • 18. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
    Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, Chen ZH, Chen HJ, Guo AL, Lin QX, Wu YL.
    Cancer Chemother Pharmacol; 2011 Mar 15; 67(3):637-46. PubMed ID: 20495920
    [Abstract] [Full Text] [Related]

  • 19. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun 15; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 20. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.